Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Jeffrey AldrichXerxes PundoleSudhakar TummalaNicolas PalaskasClark R AndersenMahran ShoukierNoha Abdel-WahabAnita DeswalMaria E Suarez-AlmazorPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
ICI-myositis is a rare but severe adverse event. More than half of the patients presented with overlap manifestations and had deleterious outcomes, including respiratory failure and death. None of the patients with ICI-myositis alone died as a result of adverse events. Optimal treatment strategies have yet to be determined.
Keyphrases
- respiratory failure
- interstitial lung disease
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- myasthenia gravis
- ejection fraction
- mechanical ventilation
- systemic sclerosis
- extracorporeal membrane oxygenation
- oxidative stress
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- type diabetes
- emergency department
- metabolic syndrome
- young adults
- patient reported outcomes
- weight loss
- insulin resistance
- drug induced
- patient reported
- lymph node metastasis
- childhood cancer